Quantitative single photon emission computed tomography derived standardized uptake values on 99mTc-PYP scan in patients with suspected ATTR cardiac amyloidosis.
Amyloid
Cardiooncology
Heart failure
Multimodality imaging
Nuclear imaging
Radiology
Journal
Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology
ISSN: 1532-6551
Titre abrégé: J Nucl Cardiol
Pays: United States
ID NLM: 9423534
Informations de publication
Date de publication:
02 2023
02 2023
Historique:
received:
19
07
2021
accepted:
02
04
2022
pubmed:
3
6
2022
medline:
8
3
2023
entrez:
2
6
2022
Statut:
ppublish
Résumé
Technetium-99 pyrophosphate scintigraphy (99mTc-PYP) provides qualitative and semiquantitative diagnosis of ATTR cardiac amyloidosis (ATTR-CA) using the Perugini scoring system and heart/contralateral heart ratio (H/CL) on planar imaging. Standardized uptake values (SUV) with quantitative single photon emission computed tomography (xSPECT/CT) can offer superior diagnostic accuracy and quantification through precise myocardial contouring that enhances assessment of ATTR-CA burden. We examined the correlation of xSPECT/CT SUVs with Perugini score and H/CL ratio. We also assessed SUV correlation with cardiac magnetic resonance (CMR), echocardiographic, and baseline clinical characteristics. Retrospective review of 78 patients with suspected ATTR-CA that underwent 99mTc-PYP scintigraphy with xSPECT/CT. Patients were grouped off Perugini score (Grade 0-1 and Grade 2-3), H/CL ratio (≥ 1.5 and < 1.5). Two cohorts were also created: myocardium SUV
Identifiants
pubmed: 35655113
doi: 10.1007/s12350-022-02988-5
pii: 10.1007/s12350-022-02988-5
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
127-139Commentaires et corrections
Type : CommentIn
Type : CommentIn
Informations de copyright
© 2022. The Author(s) under exclusive licence to American Society of Nuclear Cardiology.
Références
Ruberg FL, Berk JL. Transthyretin (TTR) cardiac amyloidosis. Circulation 2012;126:1286‐300. https://doi.org/10.1161/CIRCULATIONAHA.111.078915 .
doi: 10.1161/CIRCULATIONAHA.111.078915
pubmed: 22949539
pmcid: 3501197
Gilstrap L, Dominici F, Wang Y, et al. Epidemiology of cardiac amyloidosis-associated heart failure hospitalizations among fee-for-service medicare beneficiaries in the United States. Circulation 2019;12:e005407. https://doi.org/10.1161/CIRCHEARTFAILURE.118.005407 .
doi: 10.1161/CIRCHEARTFAILURE.118.005407
pubmed: 31170802
Bokhari S, Castaño A, Pozniakoff T, Deslisle S, Latif F, Maurer MS. (99m)Tc-pyrophosphate scintigraphy for differentiating light-chain cardiac amyloidosis from the transthyretin-related familial and senile cardiac amyloidosis. Circ Cardiovasc Imaging 2013;6:195‐201. https://doi.org/10.1161/CIRCIMAGING.112.000132 .
doi: 10.1161/CIRCIMAGING.112.000132
pubmed: 23400849
pmcid: 3727049
Rapezzi C, Quarta CC, Guidalotti PL, et al. Role of (99m)Tc-DPD scintigraphy in diagnosis and prognosis of hereditary transthyretin-related cardiac amyloidosis. JACC Cardiovasc Imaging 2011;4:659‐70. https://doi.org/10.1016/j.jcmg.2011.03.016 .
doi: 10.1016/j.jcmg.2011.03.016
pubmed: 21679902
de Haro-del Moral FJ, Sánchez-Lajusticia A, Gómez-Bueno M, García-Pavía P, Salas-Antón C, Segovia-Cubero J. Role of cardiac scintigraphy with
doi: 10.1016/j.recesp.2011.12.015
pubmed: 22464102
Treglia G, Glaudemans AWJM, Bertagna F, et al. Diagnostic accuracy of bone scintigraphy in the assessment of cardiac transthyretin-related amyloidosis: a bivariate meta-analysis. Eur J Nucl Med Mol Imaging 2018;45:1945‐55. https://doi.org/10.1007/s00259-0180-4013-4 .
doi: 10.1007/s00259-0180-4013-4
pubmed: 29687207
Poterucha T, Elias P, Bokhari S, et al. Diagnosing transthyretin cardiac amyloidosis by technetium 99m pyrophosphate: a test in evolution. JACC 2020. https://doi.org/10.1016/j.jcmg.2020.08.027 .
doi: 10.1016/j.jcmg.2020.08.027
pubmed: 33221204
pmcid: 8301717
Bokhari S, Shahzad R, Castaño A, Maurer MS. Nuclear imaging modalities for cardiac amyloidosis. J Nucl Cardiol 2014;21:175‐84. https://doi.org/10.1007/s12350-013-9803-2 .
doi: 10.1007/s12350-013-9803-2
pubmed: 24162886
pmcid: 4302756
Ramsay S, Lindsay K, Fong W, et al. Tc-HDP quantitative SPECT/CT in transthyretin cardiac amyloid and the development of a reference interval for myocardial uptake in non-affected population. Eur J Hybrid Imaging. 2018. https://doi.org/10.1186/s41824-018-0035-1 .
doi: 10.1186/s41824-018-0035-1
pubmed: 30175320
Hafeez AS, Bavry AA. Diagnosis of transthyretin amyloid cardiomyopathy. Cardiol Ther. 2020;9:85‐95. https://doi.org/10.1007/s40119-020-00169-4 .
doi: 10.1007/s40119-020-00169-4
pubmed: 32266575
pmcid: 7237598
Ben-Haim S, Chicheportiche A, Goshen E, et al. Quantitative SPECT/CT parameters of myocardial
doi: 10.1186/s13550-021-00828-0
pubmed: 34487268
pmcid: 8421473
Masri A, Bukhari S, Ahmad S, et al. Efficient 1-hour technetium-99 m pyrophosphate imaging protocol for the diagnosis of transthyretin cardiac amyloidosis. Circ Cardiovasc Imaging 2020;13:e010249. https://doi.org/10.1161/CIRCIMAGING.119.010249 .
doi: 10.1161/CIRCIMAGING.119.010249
pubmed: 32063053
pmcid: 7032611
Scully PR, Morris E, Patel KP, et al. DPD quantification in cardiac amyloidosis: a novel imaging biomarker [published correction appears in JACC Cardiovasc Imaging. 2021 Jan;14(1):318-319]. JACC Cardiovasc Imaging 2020;13:1353‐63. https://doi.org/10.1016/j.jcmg.2020.03.020 .
doi: 10.1016/j.jcmg.2020.03.020
pubmed: 32498921
pmcid: 7264710
Banypersad SM. The evolving role of cardiovascular magnetic resonance imaging in the evaluation of systemic amyloidosis. Magn Reson Insights. 2019. https://doi.org/10.1177/1178623X19843519 .
doi: 10.1177/1178623X19843519
pubmed: 31068754
pmcid: 6495435
Pagourelias ED, Mirea O, Duchenne J, et al. Echo parameters for differential diagnosis in cardiac amyloidosis: a head-to-head comparison of deformation and nondeformation parameters. Circ Cardiovasc Imaging 2017;10:e005588. https://doi.org/10.1161/CIRCIMAGING.116.005588 .
doi: 10.1161/CIRCIMAGING.116.005588
pubmed: 28298286
Lee J, Kim K, Choi JO, Kim SJ, Jeon ES, Choi JY. 99mTc-DPD scintigraphy and SPECT/CT in patients with AL and ATTR type amyloidosis: potential clinical implications. Medicine (Baltimore) 2020;99:e18905. https://doi.org/10.1097/MD.0000000000018905 .
doi: 10.1097/MD.0000000000018905
pubmed: 31977903
Sperry BW, Gonzalez MH, Brunken R, Cerqueira MD, Hanna M, Jaber WA. Non-cardiac uptake of technetium-99m pyrophosphate in transthyretin cardiac amyloidosis. J Nucl Cardiol 2019;26:1630‐7. https://doi.org/10.1007/s12350-017-1166-7 .
doi: 10.1007/s12350-017-1166-7
pubmed: 29344917
Dorbala S, Park MA, Cuddy S, et al. Absolute Quantitation of Cardiac
doi: 10.2967/jnumed.120.247312
pubmed: 32887756
pmcid: 8844269
Maurer MS, Schwartz JH, Gundapaneni B, et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med 2018;379:1007‐16. https://doi.org/10.1056/NEJMoa1805689 .
doi: 10.1056/NEJMoa1805689
pubmed: 30145929
Yamamoto H, Yokochi T. Transthyretin cardiac amyloidosis: an update on diagnosis and treatment. ESC Heart Fail. 2019;6:1128‐39. https://doi.org/10.1002/ehf2.12518 .
doi: 10.1002/ehf2.12518
pubmed: 31553132
pmcid: 6989279
Garcia-Pavia P, Rapezzi C, Adler Y, et al. Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases. Eur Heart J 2021. https://doi.org/10.1093/eurheartj/ehab072 .
doi: 10.1093/eurheartj/ehab072
pubmed: 34263907
pmcid: 8380059